More reddit from Q&A portion...
Braden1440
5 minutes ago
CD 16 Questions
Primary endpoint of CD16
Patients who are alive and free from respiratory failure.
This primary endpoint has a high probability of being hit.
-Interim Analysis will be done
-MHRA has already said they will accept this as long as it reaches statistical significance
Drug will be administered plus the SoC
Braden1440
4 minutes ago
We will not be uplisted to Nasdaq until:
We achieve revenue. The company strongly believes we will generate revenue upon approval in the near future and currently has $99 million on hand of Leronlimab ready to be sold.
We need increased stockholder value but have a plan ready to go. As of December, we were at -$6.5 million
Stock price needs to be seasoned over $4. If below $4, we need to pass a Net Tangible Asset test over $2 million. Which we are currently at -$18 million.
So, we’re hinging getting revenue.